ClinicalTrials.gov Search Results 04/11/2020

	Title	Status	Study Results	Conditions	Interventions	Locations
1	Application of Desferal to Treat COVID-19	Recruiting	No Results Available	•COVID-19	Drug: Deferoxamine	 Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of
2	Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19	Active, not recruiting	No Results Available	•COVID-19	Drug: Favipiravir Other: Placebo	Asst Fatebenefratelli Sacco, Milano, Italy
3	COVID-19 Symptom Tracker	Recruiting	No Results Available	•COVID-19	Other: No Intervention	 Massachusetts General Hospital, Boston, Massachusetts, United States King's College London, London, United Kingdom
4	Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.	Recruiting	No Results Available	•COVID-19	 Drug: Aspirin 75mg Drug: Clopidogrel 75mg Drug: Rivaroxaban 2.5 MG Drug: Atorvastatin 40mg Drug: Omeprazole 20mg 	Charing Cross Hospital, London, United Kingdom
5	The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19	Not yet recruiting	No Results Available	•COVID-19	Drug: Huaier Granule	
6	Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19	Recruiting	No Results Available	•COVID-19	Device: oxyhydrogen Device: Oxygen	•First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
7	DAS181 for Severe COVID-19: Compassionate Use	Recruiting	No Results Available	•COVID-19	•Drug: DAS181	•Renmin Hospital of Wuhan University, Wuhan, Hubei, China
8	Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19	Not yet recruiting	No Results Available	•COVID-19	 Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants Dietary Supplement: isocaloric/ isonutrigenous ONS 	
9	Study of Open Label Losartan in COVID-19	Recruiting	No Results Available	•COVID-19	Drug: Losartan	 University of Kansas Medical Center, Kansas City, Kansas, United States
10	Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia	Recruiting	No Results Available	COVID-19 Pneumonia	•Drug: Best supportive Care (BSC) + IFX-1 •Drug: Best supportive care only	•University Amsterdam, Amsterdam, Netherlands
11	ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease	Not yet recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine	•University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada
12	Hyperimmune Plasma for Critical Patients With COVID-19	Active, not recruiting	No Results Available	•COVID-19	Other: hyperimmune plasma	Catherine Klersy, Pavia, PV, Italy
13	Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection	Not yet recruiting	No Results Available	•COVID-19	Drug: 1: Naproxen Drug: 2: Standard of care	
14	Traditional Chinese Medicine for Severe COVID-19	Not yet recruiting	No Results Available	•COVID-19	•Drug: Traditional Chinese Medicine Prescription	•Hao Li, Beijing, Beijing, China
15	Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia	Recruiting	No Results Available	•COVID-19	Biological: UC-MSCs Other: Placebo	Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China
16	Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.	Recruiting	No Results Available	•COVID-19	•Drug: TCM prescriptions	•Huai'an fourth people's Hospital, Huaian, Jiangsu, China
17	Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19	Withdrawn	No Results Available	•COVID-19	 Drug: Recombinant human angiotensin- converting enzyme 2 (rhACE2) 	•GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
18	A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19	Recruiting	No Results Available	•COVID-19	Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells	Chongqing Public Health Medical Center, Chongqing, China

	Title	Status	Study Results	Conditions	Interventions	Locations
19	Safety and Efficacy of Baricitinib for COVID-19	Not yet recruiting	No Results Available	•COVID-19	Drug: Baricitinib	•University of Colorado, Denver, Aurora, Colorado, United States
20	Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients	Not yet recruiting	No Results Available	•COVID-19	 Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine sulfate Drug: Baricitinib (janus kinase inhibitor) Drug: Sarilumab (anti-IL-6 receptor) 	Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
21	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19	Recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine Drug: Azithromycin	Intermountain Medical Center, Murray, Utah, United States University of Utah, Salt Lake City, Utah, United States
22	Epidemiological Observation From a Smartphone Self- monitoring Application for Suspected COVID-19 Patients' Triage	Recruiting	No Results Available	•COVID-19	Device: Web application users	•All French Emergency services, Le Mans, France
23	Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)	Recruiting	No Results Available	•COVID-19 Pneumonia	Drug: Tocilizumab Injection	 Azienda Ospedaliera "SS. Antonio e Biagio e C. Arrigo" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy Azienda Ospedaliero-Universitaria di Modena, Modena, Italy A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy and 17 more
24	A Trial of Ciclesonide in Adults With Mild COVID-19	Not yet recruiting	No Results Available	•COVID-19	Drug: Ciclesonide Metered Dose Inhaler [Alvesco]Drug: Hydroxychloroquine	
25	The COVID-19 Mobile Health Study (CMHS)	Recruiting	No Results Available	•COVID-19	 Other: nCapp, a cell phone-based auto- diagnosis system 	•Renmin Hospital of Wuhan University, Wuhan, Hubei, China
26	Mild COVID-19 Peginterferon Lambda	Not yet recruiting	No Results Available	•COVID-19	•Drug: Peginterferon Lambda-1a •Other: Standard of Care Treatment	
27	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	Not yet recruiting	No Results Available	•COVID-19	 Drug: Hydroxychloroquine Drug: Placebo of Hydroxychloroquine Drug: Lopinavir and ritonavir Drug: Placebo of LPV/r Tablets 	CHU d'Angers, Angers, France AP-HP - Hôpital Bichat, Paris, France CHU de Saint-Etienne, Saint-Étienne, France
28	<u>Dynamic Evaluation of COVID-19 Diagnostic Tests</u>	Not yet recruiting	No Results Available	•COVID-19	•Diagnostic Test: COVID-19 diagnostic test	

	Title	Status	Study Results	Conditions	Interventions	Locations
29	Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19	Recruiting	No Results Available	•COVID-19	Drug: Sarilumab Drug: Placebo	 Regeneron Study Site, Los Angeles, California, United States Regeneron Study Site, Sacramento, California, United States Regeneron Study Site, Santa Monica, California, United States Regeneron Study Site, Aurora, Colorado, United States Regeneron Study Site, Denver, Colorado, United States Regeneron Study Site, New Haven, Connecticut, United States Regeneron Study Site, Washington, District of Columbia, United States Regeneron Study Site, Coral Gables, Florida, United States Regeneron Study Site, Gainesville, Florida, United States Regeneron Study Site, Orlando, Florida, United States and 53 more
30	Beat COVID-19 - Observational Trial	Recruiting	No Results Available	•COVID-19		Beat COIVD, LLC, Chicago, Illinois, United States
31	Treatment of COVID-19 Patients With Anti-interleukin Drugs	Recruiting	No Results Available	•COVID-19	Other: Usual Care Drug: Anakinra Drug: Siltuximab Drug: Tocilizumab	 AZ Sint-Jan Brugge, Brugge, Belgium University Hospital Saint-Pierre, Brussels, Belgium Erasmus University Hospital, Brussels, Belgium University Hospital Saint-Luc, Brussels, Belgium University Hospital Antwerp, Edegem, Belgium Ziekenhuis Oost-Limurg, Genk, Belgium University Hospital Ghent, Gent, Belgium University Hospital Brussels, Jette, Belgium University Hospital Liège, Liège, Belgium
32	Hyperbaric Oxygen for COVID-19 Patients	Recruiting	No Results Available	•COVID-19	•Device: hyperbaric oxygen therapy (HBOT)	NYU Winthrop Hospital, Mineola, New York, United States
33	A Pilot Study of Sildenafil in COVID-19	Recruiting	No Results Available	•COVID-19	Drug: Sildenafil citrate tablets	•Department and Institute of Infectious Disease, Wuhan, Hubei, China
34	Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)	Recruiting	No Results Available	•COVID-19	Drug: Sargramostim Other: Control	AZ Sint Jan Brugge, Brugge, Belgium University Hospital Ghent, Gent, Belgium
35	Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System	Recruiting	No Results Available	•COVID-19	Other: Surgical facial mask	Rigshospitalet, Copenhagen, Denmark
36	CAP-1002 in Severe COVID-19 Disease	Available	No Results Available	•COVID-19	Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells	Cedars-Sinai Medical Center, Los Angeles, California, United States
37	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease	Not yet recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine Drug: Placebo	•Institute for Tropical Medicine, Tübingen, Germany
38	A Study of Quintuple Therapy to Treat COVID-19 Infection	Not yet recruiting	No Results Available	•COVID-19	 Drug: Hydroxychloroquine Drug: Azithromycin Dietary Supplement: vitamin C Dietary Supplement: Vitamin D Dietary Supplement: Zinc 	ProgenaBiome, Ventura, California, United States
39	The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19	Recruiting	No Results Available	•COVID-19		 Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark Regionshospitalet Horsens., Horsens, Denmark
40	Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia	Not yet recruiting	No Results Available	•COVID-19	Drug: Sirolimus Drug: Placebo	

	Title	Ctatua	Ctudy Doorite	Conditions	Interventions	Longtions
	Title	Status	Study Results	Conditions	Interventions	Locations
41	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	Not yet recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine Sulfate 400 mg twice a day	University of Pennsylvania, Philadelphia, Pennsylvania, United States
					Drug: Hydroxychloroquine Sulfate 600 mg twice a day	
					Drug: Hydroxychloroquine Sulfate 600 mg once a day	
					Placebo oral tablet	
42	Treatments for COVID-19: Canadian Arm of the SOLIDARITY	Recruiting	No Results Available	•COVID-19	Drug: Lopinavir/ritonavir	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
	<u>Trial</u>					 Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
43	ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19	Not yet recruiting	No Results Available	•COVID-19		•IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy
44	Chloroquine for Mild Symptomatic and Asymptomatic	Not yet recruiting	No Results Available	•COVID-19	Drug: chloroquine	
	COVID-19				Other: standard care	
45	Critically III Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study	Completed	No Results Available	•COVID-19		Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
						Prince of Wales Hospital, Hong Kong, Hong Kong
						Princess Margaret Hospital, Hong Kong, Hong Kong
46	Treatment of COVID-19 Cases and Chemoprophylaxis of	Recruiting	No Results Available	•COVID-19	Drug: Antiviral treatment and prophylaxis	Departament de Salut, Barcelona, Spain
	Contacts as Prevention				Other: Standard Public Health measures	
47	Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak	Recruiting	No Results Available	•COVID-19	Other: survey	Assiut University Hospitals, Assiut, Egypt
48	Hydroxychloroquine vs. Azithromycin for Outpatients in Utah	Recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine	•Intermountain Medical Center, Murray, Utah, United States
	With COVID-19				Drug: Azithromycin	•University of Utah, Salt Lake City, Utah, United States
49	Safety in Convalescent Plasma Transfusion to COVID-19	Not yet recruiting	No Results Available	•COVID-19	Biological: Convalescent Plasma	•Hospital San José, Monterrey, Nuevo Leon, Mexico
50	Recombinant Human Angiotensin-converting Enzyme 2	Not yet recruiting	No Results Available	•COVID-19	•Drug: RhACE2 APN01	Medizinische Universität Innsbruck, Innsbruck, Austria
	(rhACE2) as a Treatment for Patients With COVID-19				Physiological saline solution	Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria
						Medizinische Universität Wien, Wien, Austria
						•The National University Hospital, Rigshospitalet, Copenhagen, Denmark
						•Herlev Gentofte Hospital, Herlev, Denmark
						Nordsjællands Hospital, Hillerød, Denmark
						Hvidovre Hospital, Hvidovre, Denmark
						Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
						•Klinikum rechts der Isar, Technische Universität München, München, Germany
51	Bidirectional Oxygenation Valve in the Management of	Not yet recruiting	No Results Available	•COVID-19	•Device: GO2 PEEP MOUTHPIECE	•Emory University Hospital, Atlanta, Georgia, United States
	Pulmonary Complications of COVID-19					•Emory St. Joseph's Hospital, Atlanta, Georgia, United States
52	Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically III Patients With COVID-19 Pneumonitis	Recruiting	No Results Available	•COVID-19	Drug: Tocilizumab	•University of Chicago Medicine, Chicago, Illinois, United States
53	Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers	Enrolling by invitation	No Results Available	•COVID-19	Drug: Hydroxychloroquine	Baylor University Medical Center, Dallas, Texas, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
54	A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection	Not yet recruiting	No Results Available	•COVID-19	 Drug: Hydroxychloroquine Dietary Supplement: Vitamin C Dietary Supplement: Vitamin D Dietary Supplement: Zinc 	ProgenaBiome, Ventura, California, United States
55	The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2	Not yet recruiting	No Results Available	•COVID-19	Drug: PUL-042 Inhalation SolutionDrug: Placebo	
56	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Recruiting	No Results Available	•COVID-19	Drug: Lopinavir/ritonavir Drug: Hydroxychloroquine sulfate	Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
57	Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Not yet recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine Other: The control group will not receive hydroxychloroquine	
58	Pre-Exposure Prophylaxis With Hydroxychloroquine for High- Risk Healthcare Workers During the COVID-19 Pandemic	Recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine Drug: Placebos	•ISGlobal, Barcelona, Spain
59	Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation	Not yet recruiting	No Results Available	•COVID-19	Drug: Mavrilimumab	Virginia Commonwealth University, Richmond, Virginia, United States
60	Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients	Recruiting	No Results Available	•COVID-19	Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Other: Intravenous saline injection (Placebo)	•Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China
61	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	Recruiting	No Results Available	•COVID-19	Drug: TocilizumabDrug: HydroxychloroquineDrug: Azithromycin	Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
62	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)	Recruiting	No Results Available	•COVID-19	Drug: Standard of Care	 Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States St Joseph Hospital Eureka, Fortuna, California, United States Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States and 123 more
63	Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19	Not yet recruiting	No Results Available	•COVID-19	Biological: bacTRL-Spike Other: Placebo	 Vaccine Evaluation Center, BC Children's Research Institute, University of British Columbia., Vancouver, British Columbia, Canada Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada

	Title	Status	Study Results	Conditions	Interventions	Locations
64	The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection	Not yet recruiting	No Results Available	•COVID-19	Drug: PUL-042 Inhalation Solution Drug: Placebo	•Houston Methodist Hospital, Houston, Texas, United States
65	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19	Not yet recruiting	No Results Available	•COVID-19	Drug: Hydroxychloroquine Sulfate Drug: Azithromycin Tablets	
66	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment	Recruiting	No Results Available	•COVID-19	Drug: Remdesivir Drug: Standard of Care	 Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States St Joseph Hospital Eureka, Fortuna, California, United States Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States and 116 more
67	Non-contact ECG Sensor System for COVID19	Not yet recruiting	No Results Available	•COVID-19	Device: Non-contact ECG	
68	Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults	Not yet recruiting	No Results Available	•COVID-19 •SARS-CoV-2	Other: this study is non- interventional	•University Hospital Cologne, Cologne, NRW, Germany
69	Covid-19 Pediatric Observatory	Recruiting	No Results Available	•COVID-19	Other: hospitalized children with Covid19	 Centre Hospitalier intercommunal de Creteil, Creteil, France Assistance Publique Hôpitaux de Paris, Paris, France
70	Evaluation of Efficacy of Levamisole and Formoterol +Budesonide in Treatment of COVID-19	Not yet recruiting	No Results Available	•COVID-19	Drug: Levamisole Pill + Budesonide +Formoterol inhaler Drug: Lopinavir/Ritonavir + hydoxychloroquine	
71	NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia	Not yet recruiting	No Results Available	•COVID-19 Pneumonia	Biological: NestCell®	 Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil
72	Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT	Recruiting	No Results Available	•COVID-19 Pneumonia	Drug: Bevacizumab	Qilu Hospital of Shandong University, Jinan, Shandong, China
73	Treatment of COVID-19 Patients Using Wharton's Jelly- Mesenchymal Stem Cells	Recruiting	No Results Available	•Use of Stem Cells for COVID-19 Treatment	Biological: WJ-MSCs	•Stem Cells Arabia, Amman, Jordan

	Title	Status	Study Results	Conditions	Interventions	Locations
74	A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia	Recruiting	No Results Available	•COVID-19 Pneumonia	Drug: Tocilizumab (TCZ) Drug: Placebo	 •University of California San Diego, La Jolla, California, United States •eStudySite, La Mesa, California, United States •David Geffen School of Medicine UCLA, Los Angeles, California, United States •Denver Health Medical Center, Denver, Colorado, United States •University of Chicago, Chicago, Illinois, United States •Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States •Baystate Health System, Springfield, Massachusetts, United States •Mayo Clinic - PPDS, Rochester, Minnesota, United States •Hackensack University Medical Center, Hackensack, New Jersey, United States •James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States •and 42 more
75	Tetrandrine Tablets Used in the Treatment of COVID-19	Enrolling by invitation	No Results Available	•Corona Virus Disease 2019,COVID-19	Drug: Tetrandrine	Tetrandrine Tablets, Jinhua, Zhejiang, China
76	The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia	Not yet recruiting	No Results Available	COVID-19 Thalidomide	Drug: thalidomide Drug: placebo	
77	The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19	Not yet recruiting	No Results Available	COVID-19 Thalidomide	Drug: placebo Drug: Thalidomide	
78	Max COVID19- Study	Recruiting	No Results Available	•COVID-19		•Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India
79	Myocardial Damage in COVID-19	Enrolling by invitation	No Results Available	COVID-19 Cardiovascular Diseases	•Other: non	 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
80	Hydroxychloroquine for COVID-19	Recruiting	No Results Available	COVID-19, Hydroxychloroquine Sulfate	Drug: Hydroxychloroquine Sulfate Drug: Placebo	•Institute for Tropical Medicine, Tübingen, Germany
81	TXA and Corona Virus 2019 (COVID19) in Outpatients	Not yet recruiting	No Results Available	•COVID-19	Drug: Tranexamic acid tablets Drug: Placebo oral tablet	•University of Alabama at Birmingham, Birmingham, Alabama, United States
82	Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia	Not yet recruiting	No Results Available	•COVID-19	Drug: Siltuximab Drug: Methylprednisolone	Hospital Clínic de Barcelona, Barcelona, Spain
83	ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020	Not yet recruiting	No Results Available	•COVID-19	Orug: Chloroquine phosphate Other: Telemedicine	

	Title	Status	Study Results	Conditions	Interventions	Locations
84	Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19	Recruiting	No Results Available	Acute Respiratory Distress Syndrome Caused by COVID-19	Drug: Dexamethasone	 ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain AVI, Hospital Clinic, Barcelona, Spain Cardiac ICU, Hospital Clinic, Barcelona, Spain Department of Anesthesia, Hospital Clinic, Barcelona, Spain Hepatic ICU, Hospital Clínic, Barcelona, Spain UVIR, Hospital Clinic, Barcelona, Spain Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain and 14 more
85	Fingolimod in COVID-19	Recruiting	No Results Available	Coronavirus Disease (COVID-19)	•Drug: Fingolimod 0.5 mg	•Wan-Jin Chen, Fuzhou, China
86	Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)	Not yet recruiting	No Results Available	COVID-19 Severe Acute Respiratory Syndrome	Drug: Hydroxychloroquine Drug: Placebo oral tablet	
87	Defibrotide in COVID-19 Pneumonia	Not yet recruiting	No Results Available	 Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure 	Drug: Defibrotide Injection	
88	COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study	Recruiting	No Results Available	•COVID-19 •Liver Cirrhosis		 Dalian Sixth People's Hospital, Dalian, China Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China The First Hospital of Lanzhou University, Lanzhou, China The Central Hospital of Lishui City, Lishui, China Guangxi Zhuang Autonomous Region, Nanning, China The Sixth Peoples Hospital of Shenyang, Shenyang, China Shenzhen Third People's Hospital, Shenzhen, China Suizhou Hospital, Hubei University of Medicine, Suizhou, China Tianjin Second People's Hospital, Tianjin, China and 5 more
89	Hypertension in Patients Hospitalized With COVID-19	Active, not recruiting	No Results Available	•COVID-19 •Hypertension		•Hankou Hospital, Hankou, Hubei, China
90	Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness	Available	No Results Available	•Severe/Very Severe COVID-19 Illness	Drug: Ruxolitinib	
91	Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial	Not yet recruiting	No Results Available	COVID-19 Respiratory Failure	Drug: AzithromycinDrug: HydroxychloroquineDrug: Placebo	
92	Azithromycin for COVID-19 Treatment in Outpatients Nationwide	Not yet recruiting	No Results Available	•COVID-19 •SARS-CoV-2	Drug: Azithromycin Drug: Placebos	•University of California San Francisco, San Francisco, California, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
93	Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine	Recruiting	Study Results No Results Available	•COVID-19	Interventions • Drug: BCG Vaccine • Drug: Placebo	 Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands Radboud UMC, Nijmegen, Gelderland, Netherlands Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands
94	Treatment of SARS Caused by COVID-19 With Ruxolitinib	Not yet recruiting	No Results Available	COVID-19 Severe Acute Respiratory Syndrome Coronavirus 2	Drug: Ruxolitinib Oral Tablet	 University Medical Center Utrecht, Utrecht, Netherlands Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico
95	Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)	Not yet recruiting	No Results Available	Coronavirus Disease 2019 COVID-19	•Drug: TJ003234 •Drug: Placebo	 OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States Indiana University Health, Indianapolis, Indiana, United States Oschner Medical Center, New Orleans, Louisiana, United States
96	Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia	Not yet recruiting	No Results Available	•COVID-19 Pneumonia		
97	The Vietnam Chloroquine Treatment on COVID-19	Not yet recruiting	No Results Available	•SARS-CoV-2 Infection •COVID-19	Drug: Chloroquine phosphate	 National Hospital for Tropical Diseases, Hanoi, Vietnam Can Gio COVID Hospital, Ho Chi Minh City, Vietnam Cho Ray Hospital, Ho Chi Minh City, Vietnam Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
98	Impact of the Coronavirus (COVID-19) on Patients With Cancer	Not yet recruiting	No Results Available	•Cancer •COVID-19		
99	CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment	Recruiting	No Results Available	Severe Coronavirus Disease (COVID-19)	Drug: CD24Fc Drug: Placebo	•Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States
100	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19	Not yet recruiting	No Results Available	•SARS-CoV-2 •COVID-19	Combination Product: Hydroxychloroquine Sulfate + Azithromycin Drug: Hydroxychloroquine Sulfate	 Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States The University Hospital, Newark, New Jersey, United States

340 additional studies not shown

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services